Skip to content
Axe Capital logo Axe Capital Trading News

Axe Capital Investments

Clear market notes built around the JSE, the rand, and what matters locally.

Axe Capital Trading News shares simple market takes on the stories moving South African shares, the rand, and a handful of major currency pairs.

What you will find here:

1. JSE shares, South African companies, and the local knock-on effects of big market news.

2. The rand, interest rates, and a small group of forex pairs, with USD/ZAR at the centre.

3. Global stories only when they can actually change how a local investor might act.

Latest market stories

Why D-Wave Quantum Stock Popped Today
2026-08-03 19:24 The Motley Fool Neutral Axe Cap view: Neutral

D-Wave Quantum stock surged 10.7% after investment bank Wedbush initiated coverage with an outperform rating and $40 price target. Despite being unprofitable with only $12.4 million in annual revenue, Wedbush argues quantum computing companies should be valued on engineering and physics milestones rather than traditional profitability metrics. However, analysts forecast D-Wave will continue losing money through at least 2030 and may run out of cash by 2031.

Axe note: D-Wave’s stock jump on positive analyst coverage clashes with ongoing losses and an unclear path to profit.

Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors?
2026-08-03 19:17 The Motley Fool Positive Axe Cap view: Selective

Michael R. Hayden, a director at Ionis Pharmaceuticals, purchased 20,000 shares worth $1.1 million on July 30-31, 2026, increasing his total holdings by 34%. The insider purchase signals confidence in the company's RNA-targeted therapy pipeline, which includes recently approved drugs like Tryngolza and upcoming treatments for Alexander disease and Angelman syndrome. Despite current net losses of $564.8 million, the company maintains $873.8 million in trailing twelve-month revenue and an $8.8 billion market valuation.

Axe note: A director’s $1.1 million buy signals confidence in Ionis’ drug pipeline but doesn’t directly impact JSE-listed stocks.

Joby Aviation's Next Earnings Report on Aug. 5 Could Send the Stock Plummeting. Here's Why.
2026-08-03 19:15 The Motley Fool Negative Axe Cap view: Bearish

Joby Aviation faces critical pressure ahead of its Q2 2026 earnings report on Aug. 5. Despite a 50% stock decline in 2026 and positive announcements including NYC flight demonstrations and partnerships with Toyota, Virgin Atlantic, Delta, and Uber, investors are focused on FAA type certification progress. The company needs concrete regulatory milestones to avoid another stock decline, as vague certification updates could disappoint the market.

Axe note: Without clear progress on FAA certification, Joby’s upcoming report may trigger renewed losses despite big-name partnerships.

What we follow

We keep the focus on JSE shares, the rand, and the currency moves that matter most to South African investors.

JSE and rand